33 Biotechnology & Immunology
Advanced Technology for Creating Vascularised Kidney Organoids
AMSBIO recently conducted an interview with Professor Ryuji Morizane, a distinguished expert in renal research at Harvard Medical School. Professor Morizane’s groundbreaking research, which combines organoid and bioengineering technology, has led to the development of kidney organoids that incorporate a vascular system.
To support this innovative work, Professor Morizane’s research team employs StemFit®, a chemically-defined culture medium without human or animal-derived components, for the embryonic (ES) and induced pluripotent stem cells (iPSC) used in the research. Moreover, StemFit® is a feeder-free medium.
In discussion about his research - Professor Morizane commented: “There were many challenges we had to overcome to reliably produce vascularised renal organoids. In the past, we used to culture hPSCs with feeder cells, however frequent passaging and the removal process of feeder cells often lead to variations in cell quality. Using StemFit® culture medium, has allowed us to eliminate the use of feeder-culture, meaning we can produce a larger stock of iPSCs. This, combined with frequent checking of progenitor cell differentiation efficacy, has helped our researchers reduce batch-to-batch variation. Switching to StemFit® has also improved cell viability and growth, enabling us to improve gene-editing efficacy, and the production of more cells for experimentation.”
He added: ”Our renal organoid technology shows great promise for use in disease modelling and toxicity testing. In the future, I would like to focus on translational research such as drug screening using kidney organoids – and also consider clinical applications. Here the challenge is to produce high-quality cells used for transplantation. For these new applications it is necessary that we develop cost-efficient culture methods to produce iPSCs and the differentiation protocols of organoids.”
AMSBIO’s StemFit® series of chemically-defined media, which are free of animal-derived components, have been demonstrated to effectively maintain induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) in feeder-free conditions throughout the stem cell culture reprogramming, expansion, and differentiation phases. StemFit® is available in both research and GMP grade formulations, and is the market leader in colony-forming efficiency, with lower media volume consumption compared to leading competitors, resulting in the most cost-effective colony expansion. StemFit® is a component of AMSBIO’s Stem Cell Synergy Solution product line for streamlining and improving ES/iPS Cell Culture efficiency, from basic research to clinical applications.
To read the interview in full please visit
ilmt.co/PL/GbQV More information online:
ilmt.co/PL/D3bV
59900pr@reply-direct.com Streamlining Cell Analysis Workfl ows for the Immuno-
Oncology, Virology and Vaccine Development Markets Agilent Technologies Inc has introduced an integrated solution that combines their xCELLigence RTCA HT platform with the BioTek BioSpa 8 Automated Incubator. This new development offers a higher level of workflow automation, allowing for the creation of label-free high-throughput potency assays for immuno-oncology and high-throughput viral cytopathic effects (CPE) assays for the vaccine market.
Pharmaceutical researchers in immuno-oncology and vaccine developers are seeking new ways to accelerate clinical success and respond to public health threats. While automated workflows offer the potential to increase drug candidate screening and improve the efficiency of research, many current solutions rely on manual steps that slow down throughput and restrict assay development.
The integration of xCELLigence RTCA HT and BioSpa 8 offers a non-invasive, label-free kinetic readout of cell proliferation and cytotoxicity. With the ability to analyse up to eight 384-well E-Plates, this system increases throughput and reduces sample sizes. The BioSpa 8 provides real-
time temperature and CO2/O2 control with humidity monitoring while the xCELLigence instrument is equipped with a heated cradle to protect cells from unnecessary perturbations during the automated transfer from the incubator. Automated assays and data analysis software make this a user-friendly, walk-away system for identifying disease-fighting therapeutics, offering a level of automation unique to this technology combination.
“This is an innovative solution for immuno-oncology therapeutic and vaccine development, demonstrating Agilent’s ongoing commitment to fight cancer and infectious diseases,” said Todd Christian, Vice President and General Manager of Agilent’s Cell Analysis Division. “Integrating our non-invasive, and real-time cell analysis measurement capabilities and physiological incubation provides a simple, automated workflow for increased throughput and screening flexibility under physiological conditions.”
“The xCELLigence RTCA HT technology has been key to facilitating high-throughput, rapid, and quantitative cytopathic effect (CPE) monitoring as a tool to assess neutralising activity and potency,” said Dr Robert Carnahan, Associate Director of the Vanderbilt Vaccine Center at the Vanderbilt University Medical Center. “We were able to bypass a multitude of hands-on, multistep processes required by plaque or focus-forming assays to measure viral activity.”
More information online:
ilmt.co/PL/BKnK 59868pr@reply-direct.com
Hydrogel Reagent Kits for Agarose Encapsulation and 3D Cell Culture Research
Dolomite Bio’s hydrogel focused reagent kits enable high-throughput encapsulation of cells in hydrogel scaffolds. The nadAROSE and nadia3D kits address the needs of researchers exploring both agarose encapsulation and collagen-based hydrogel projects for the 3D cell culture space.
Current methods for constructing hydrogel scaffolds involve costly, time consuming, ‘home brew’ batch methods, with few commercially available solutions. For this reason, Dolomite Bio is launching the nadAROSE kit for the encapsulation of cells in agarose and the nadia3D kit for 3D cell culture research. Both kits are complete, standardised, and reliable solutions, containing all the single use, prefabricated consumables needed for scaffold production on the Nadia Instrument.
Due to the flexible nature of the Nadia Instrument, researchers can perform high throughput encapsulation of up to 1 million cells in one run, with a choice of running 1,2,4 or 8 lanes in parallel, in under 30 minutes. The fully automated Nadia Instrument guides users through all relevant steps of the experiment via an easy-to-use touchscreen interface. With single use chips and precise temperature control, the Nadia instrument is ideally suited for your hydrogel research projects. Additionally, researchers will benefit from the wide sample compatibility, opening up research areas involving large cells of over 50 µm in diameter, such as cardiomyocytes.
Most importantly, both kits can offer control over mono-clonality, giving researchers access to a variety of downstream workflows, such as, cell secretion studies, cell- cell interactions, microbial cell culture. Furthermore, the nadAROSE kit is compatible with cytometric analyses. The nadia3D kit opens up downstream workflows in: the development of novel culture techniques for fastidious cell lines, disease modelling, identification of novel drug targets and pharmaceutical screening.
More information online:
ilmt.co/PL/O2lm 58306pr@reply-direct.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56
